Acipimox (sodium)

• Description :

  Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].

• Product Name Alternative :

  K-9321 (sodium)

• UNSPSC :

  12352005

• Target :

  Carbonic Anhydrase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/acipimox-sodium.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C[N+]([O-])=C(C)C=N1)O[Na]

• Molecular Formula :

  C6H5N2NaO3

• Molecular Weight :

  176.11

• References & Citations :

  [1]Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83 (12) :2671-2677.|[2]Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174 (2) :267-72.|[3]Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171 (2) :161-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [76958-97-9]